ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Is 3 Really What We Need? Relative Effectiveness of Benzathine Penicillin G and Doxycycline Treatment Regimens for Late or Unknown Duration Syphilis in 6 US Jurisdictions, 2016-2021.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Key Considerations in Evaluating Syphilis Therapeutics.Sexually transmitted diseases · 2026Article
- Serological response after shorter durations of therapy for syphilis of late latent or unknown duration: What does it mean?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Strong Real-World Evidence That a Single Dose of Benzathine Penicillin G or a 28-Day Course of Oral Doxycycline Is Not Inferior to 3 Doses of Benzathine Penicillin G for the Treatment of Late Latent or Unknown Duration Syphilis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Expanding treatment options for syphilis during pregnancy: a review of alternatives to penicillin.Frontiers in global women's health · 2026Review
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
Abstract
backgroundLittle evidence supports the need for 3 weekly benzathine penicillin G (BPG) injections to treat late or unknown duration syphilis, and completion of the regimen may be difficult. We compared treatment effectiveness of 1 versus 3 doses of BPG and doxycycline.
methodsWe conducted a retrospective cohort study using surveillance data for cases diagnosed with late or unknown duration syphilis between 2016 and 2021 from 6 jurisdictions. We categorized BPG and doxycycline treatment based on the recorded number and timing of doses received. We defined treatment effectiveness as a 4-fold decrease in nontreponemal serum titer by 24 months posttreatment and compared treatment effectiveness using log binomial regression.
resultsAmong 18 027 cases eligible for inclusion, over half had 3 doses of BPG recorded (11 342, 63%); relatively few had only 1 dose recorded (1928, 11%) or received at least 28 days of doxycycline (3017, 17%). Fourfold titer decreases were observed for 75% and 80% of cases given 3 doses and 1 dose of BPG, respectively, and for the 74% given doxycycline. Treatment effectiveness was similar across all treatment dose/interval categories and remained comparable when stratified by baseline titer, pregnancy status, and human immunodeficiency virus (HIV) infection.
conclusionsWe did not observe a difference in treatment effectiveness between 1 and 3 doses of BPG, or between 3 doses of BPG and doxycycline, for late or unknown duration syphilis. Additional observational and clinical studies with more complete treatment and serologic response information are needed to confirm these findings and inform practice recommendations.
Indexed as
Identifiers
41725190What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.